Compare U & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | U | GKOS |
|---|---|---|
| Founded | 2004 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 8.7B |
| IPO Year | 2020 | 2015 |
| Metric | U | GKOS |
|---|---|---|
| Price | $29.59 | $147.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 12 |
| Target Price | $36.61 | ★ $126.92 |
| AVG Volume (30 Days) | ★ 7.2M | 878.3K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,849,648,000.00 | $507,442,000.00 |
| Revenue This Year | $15.81 | $23.32 |
| Revenue Next Year | $12.93 | $27.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 2.01 | ★ 32.33 |
| 52 Week Low | $16.78 | $73.16 |
| 52 Week High | $52.15 | $148.62 |
| Indicator | U | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 57.64 | 66.35 |
| Support Level | $24.82 | $96.44 |
| Resistance Level | $29.96 | N/A |
| Average True Range (ATR) | 1.43 | 5.50 |
| MACD | 0.18 | 1.62 |
| Stochastic Oscillator | 70.83 | 90.25 |
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run, and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC, and other Americas, and key revenue is derived from the EMEA region. Its products are used in the gaming industry, retail, automotive, architecture, engineering, and construction.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.